Tri Locum Partners LP Chemo Centryx, Inc. Transaction History

Tri Locum Partners LP

$374 Million
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $3.83 Million - $6.86 Million	249,205 Added 84.1%	545,532 $13.5 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $3.11 Million - $5.48 Million	-139,973 Reduced 32.08%	296,327 $7.43 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $7.72 Million - $17 Million	420,255 Added 2619.23%	436,300 $15.9 Million
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $211,473 - $318,172	16,045 New	16,045 $274,000
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $8.23 Million - $11.4 Million	-166,077 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $7.85 Million - $10.8 Million	166,077 New	166,077 $10.3 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.